Cytrx Corp – ‘10-K’ for 12/31/12

On:  Monday, 3/11/13, at 8:29am ET   ·   For:  12/31/12   ·   Accession #:  799698-13-5   ·   File #:  0-15327

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Form 10-K for Year Ended December 31, 2012          HTML   1.18M 
 2: EX-4.8      Restricted Stock Purchase Agreement Dated December  HTML     45K 
                31, 2012, Between Cytrx Corporation and Daniel                   
                Levitt, M.D., Ph.D.                                              
 3: EX-10.19    Employment Agreement Dated January 1, 2013,         HTML     61K 
                Between Cytrx Corporation and Daniel Levitt, M.D.                
                Ph.D.                                                            
 4: EX-10.20    Employment Agreement Dated January 1, 2013,         HTML     51K 
                Between Cytrx Corporation and Benjamin S. Levin                  
 5: EX-10.21    Employment Agreement Dated January 1, 2013,         HTML     51K 
                Between Cytrx Corporation and Scott Wieland                      
 6: EX-10.22    Employment Agreement Dated January 1, 2013,         HTML     51K 
                Between Cytrx Corporation and John Y. Caloz                      
 7: EX-23.1     Consent of Experts or Counsel                       HTML     20K 
 8: EX-31.1     Certification -- §302 - SOA'02                      HTML     25K 
 9: EX-31.2     Certification -- §302 - SOA'02                      HTML     25K 
10: EX-32.1     Certification -- §906 - SOA'02                      HTML     21K 
11: EX-32.2     Certification -- §906 - SOA'02                      HTML     21K 
48: R1          Document and Entity Information                     HTML     48K 
38: R2          Consolidated Balance Sheets                         HTML    111K 
46: R3          Consolidated Balance Sheets (Parenthetical)         HTML     50K 
50: R4          Consolidated Statements of Operations               HTML     85K 
63: R5          Consolidated Statements of Stockholders' Equity     HTML     75K 
40: R6          Consolidated Statements of Cash Flows               HTML    141K 
45: R7          Nature of Business                                  HTML     27K 
35: R8          Summary of Significant Accounting Policies          HTML     66K 
27: R9          Receivables                                         HTML     25K 
64: R10         Prepaid and Other Assets                            HTML     22K 
52: R11         Short-term Investments                              HTML     27K 
51: R12         Equipment and Furnishings                           HTML     31K 
56: R13         Accrued Expenses and Other Current Liabilities      HTML     30K 
57: R14         Warrant Liabilities                                 HTML     35K 
55: R15         Commitments and Contingencies                       HTML     45K 
58: R16         Equity Transactions                                 HTML     36K 
47: R17         Investments in ADVENTRX Pharmaceuticals             HTML     25K 
49: R18         Stock Options and Warrants                          HTML    212K 
54: R19         Sale of Assets                                      HTML     23K 
68: R20         Stockholder Protection Rights Plan                  HTML     25K 
60: R21         Income Taxes                                        HTML     61K 
42: R22         Quarterly Financial Data (Unaudited)                HTML     49K 
53: R23         Schedule Ii - Valuation and Qualifying Accounts     HTML     43K 
44: R24         Summary of Significant Accounting Policies          HTML    136K 
                (Policies)                                                       
23: R25         Summary of Significant Accounting Policies          HTML     39K 
                (Tables)                                                         
61: R26         Equipment and Furnishings (Tables)                  HTML     29K 
65: R27         Accrued Expenses and Other Current Liabilities      HTML     29K 
                (Tables)                                                         
31: R28         Commitments and Contingencies (Tables)              HTML     34K 
30: R29         Stock Options and Warrants (Tables)                 HTML    214K 
33: R30         Income Taxes (Tables)                               HTML     54K 
34: R31         Quarterly Financial Data (Unaudited) (Tables)       HTML     45K 
36: R32         Nature of Business (Details)                        HTML     43K 
21: R33         Summary of Significant Accounting Policies          HTML     66K 
                (Details)                                                        
59: R34         Receivables (Details)                               HTML     22K 
41: R35         Prepaid and Other Assets (Details)                  HTML     22K 
43: R36         Short-term Investments (Details)                    HTML     29K 
25: R37         Equipment and Furnishings (Details)                 HTML     36K 
67: R38         Accrued Expenses and Other Current Liabilities      HTML     36K 
                (Details)                                                        
18: R39         Warrant Liabilities (Details)                       HTML     25K 
37: R40         Commitments and Contingencies (Details)             HTML     80K 
62: R41         Equity Transactions (Details)                       HTML     53K 
24: R42         Investments in ADVENTRX Pharmaceuticals (Details)   HTML     33K 
29: R43         Stock Options and Warrants (Details)                HTML    311K 
32: R44         Sale of Assets (Details)                            HTML     24K 
39: R45         Stockholder Protection Rights Plan (Details)        HTML     32K 
20: R46         Income Taxes (Details)                              HTML    108K 
26: R47         Quarterly Financial Data (Unaudited) (Details)      HTML     39K 
19: R48         Schedule Ii - Valuation and Qualifying Accounts     HTML     31K 
                (Details)                                                        
66: XML         IDEA XML File -- Filing Summary                      XML     94K 
28: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS   1.08M 
12: EX-101.INS  XBRL Instance -- cytr-20121231                       XML   1.66M 
14: EX-101.CAL  XBRL Calculations -- cytr-20121231_cal               XML    172K 
15: EX-101.DEF  XBRL Definitions -- cytr-20121231_def                XML    375K 
16: EX-101.LAB  XBRL Labels -- cytr-20121231_lab                     XML   1.45M 
17: EX-101.PRE  XBRL Presentations -- cytr-20121231_pre              XML    780K 
13: EX-101.SCH  XBRL Schema -- cytr-20121231                         XSD    151K 
22: ZIP         XBRL Zipped Folder -- 0000799698-13-000005-xbrl      Zip    149K 

        

To view the SGML, please refresh this page.